Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna reported Wednesday a fivefold increase in second-quarter revenue as the company pursues one of the nation’s leading vaccine candidates to fight Covid-19.

Moderna second-quarter revenue jumps fivefold on coronavirus vaccine development

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna reports second quarter 2020 financial results and provides business updates.

Moderna Reports Second Quarter 2020 Financial Results and Provides Business Updates

AstraZeneca

BioNTech SE

GlaxoSmithKline

Inovio Pharmaceuticals

Johnson & Johnson

Novavax

Pfizer

MRNA, PFE/BNTX, and AZN are leading the three vaccines in clinical phase 3 trials.

Phase 3 Trials And More: Any COVID-19 Data Is Good Data, Even If It's Bad

Coronavirus vaccine maker Moderna Inc (NASDAQ: MRNA) is scheduled to report its second-quarter results Wednesday ahead of the market open.

Coronavirus Vaccine Developer Moderna's Q2 Report: What To Expect

Moderna is expected to report a loss of ($0.36)/share on $19.83 million in revenue. Meanwhile, the so-called Whisper number is ($0.34).

Earnings Preview: What To Expect From Moderna On Wednesday

Let us take a look at five drug/biotech companies, REGN, MRNA, SRPT, ACAD and HZNP, which are gearing up for their earnings release.

Drug/Biotech Stock Q2 Earnings on Aug 5: REGN, MRNA & More

Amgen

Dynavax Technologies

Gilead Sciences

Hopes of a vaccine have once again started rising with a number of companies now entering the final phase of their trials.

Pharma Stocks in Focus on Late-Stage Coronavirus Vaccine Trials

Moderna stock has jumped by about 4x this year adding over $20 billion in market value, as investors bet that a successful Covid-19 vaccine could generate windfall profits for the clinical-stage biotech company. Is this jump in valuation warranted?

Has The Market Overpriced Moderna’s Vaccine?

Will Moderna Get Away With Charging 50% More Than Pfizer for Its Coronavirus Vaccine?

Moderna Inc (NASDAQ: MRNA) initiated a large-scale Phase 3 study of its coronavirus vaccine candidate in mid-July.

Moderna Analyst: Phase 3 Coronavirus Data Could Arrive As Soon As October

The shares have surged in the triple digits since the start of the year. And additional gains may be on the horizon.

3 Reasons to Buy Moderna Now

The shares have soared as vaccine candidates progress through human trials. Can the gains continue?

Should You Sell These Coronavirus Vaccine Stocks?

Sanofi

These Coronavirus Vaccine Makers Are Winning the Money Game So Far

The tech-heavy index kept leading the overall market upward.

Tech Giants Send Nasdaq Up 150+, but Coronavirus Vaccine Stocks Suffer on Gilead Earnings, Moderna Hack Attack

Moderna Inc (NASDAQ: MRNA), which commenced a late-stage trial of its mRNA vaccine, codenamed mRNA-1273, against SARS-CoV-2 earlier in the week, has been reportedly targeted by Chinese hackers.

Moderna Targeted By Chinese Hackers For Data Theft: Report

Moderna had a head start in advancing its COVID-19 vaccine into clinical testing. But Pfizer is ahead in some important ways.

Why Pfizer Could Be a Bigger Coronavirus Winner Than Moderna

Chinese government-linked hackers targeted biotech company Moderna Inc , a U.S.-based coronavirus vaccine research developer, this year in a bid to steal data, according to a U.S.

Exclusive: China-backed hackers 'targeted COVID-19 vaccine firm Moderna'

The coronavirus pandemic has been good news for investors in pharma companies racing to develop a Covid-19 vaccine. Stock prices for many of the competing companies are trading around record highs.

Are Covid Vaccine Stocks Worth Investing In?

The high-profile biotech says it has measures in place to guard against such attacks.

Report: China-Linked Hackers Targeted Coronavirus Vaccine Developer Moderna

iShares Nasdaq Biotechnology ETF

Covid-19 could drive biotech stocks for years to come, experts say, as investors try to pinpoint the next big winner to churn out a vaccine or treatment.
The post Why The Coronavirus Pandemic Could Influence Biotech Stocks For Years To Come appeared first on Investor's Business Daily.

Why The Coronavirus Pandemic Could Influence Biotech Stocks For Years To Come

Dr. Elizabeth “Betsy” Nabel is leaving effective immediately after sitting on the company’s board of directors for five years, Moderna said in a statement.

Moderna board member resigns to avoid conflict of interest during coronavirus vaccine trial

Shares of Moderna Inc. MRNA, -2.36% were down 0.2% in trading on Thursday after the market closed when it said a board member had resigned to avoid the perception of a conflict of interest.

Moderna board member resigns to prevent perception of conflict of interest in vaccine trial

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces resignation of Dr.

Moderna Announces Resignation of Dr. Elizabeth Nabel From Board of Directors

Moderna (MRNA) is progressing with coronavirus vaccine development. The company has initiated a late-stage study and investors will likely focus any preliminary data from the study

Coronavirus Vaccine Efforts Key to Moderna (MRNA) Q2 Earnings

Ahead of earnings from two of the most closely watched biotechs—Moderna (MRNA) and Gilead (GILD)—one thing seems pretty certain: Few investors are likely to care much less than normal about Q2 financial numbers from either.

News for Moderna Stock (MRNA)